Thromboembolism may be considered as one of the manifestations of the response of blood to injury. Other manifestations of this include hemostasis, increased vessel permeability, and vasculitis; disturbances of the microcirculation may lead to tissue injury and organ dysfunction. The factors that can initiate these changes by stimulation of platelets are exposure of subendothelial tissue (collagen, basement membrane) and intravascular stimuli such as antigen-antibody complexes, viruses, bacteria, and endotoxin. These stimuli have a number of effects on blood; the interaction of the platelets with the above stimuli leads to the release of platelet constituents including ADP; the ADP causes the platelets to adhere to each other; the aggregated platelets cause acceleration of clotting; this and changes in blood flow promote the formation of fibrin around the platelet aggregates. Some of the stimuli such as collagen and antigenantibody complexes also activate blood coagulation through factor XII; some of the materials released from these platelets affect the vessel wall. The initial platelet mass is transformed to a fibrin mass. There are compounds that inhibit the platelet release reaction, platelet aggregation, and blood coagulation and activate the fibrinolytic mechanism. It appears that by the selective use of these compounds we can improve our management of all aspects of thromboembolic disease related to vascular and intravascular stimuli.
SUMMARY
Thromboembolism may be considered as one of the manifestations of the response of blood to injury. Other manifestations of this include hemostasis, increased vessel permeability, and vasculitis; disturbances of the microcirculation may lead to tissue injury and organ dysfunction. The factors that can initiate these changes by stimulation of platelets are exposure of subendothelial tissue (collagen, basement membrane) and intravascular stimuli such as antigen-antibody complexes, viruses, bacteria, and endotoxin. These stimuli have a number of effects on blood; the interaction of the platelets with the above stimuli leads to the release of platelet constituents including ADP; the ADP causes the platelets to adhere to each other; the aggregated platelets cause acceleration of clotting; this and changes in blood flow promote the formation of fibrin around the platelet aggregates. Some of the stimuli such as collagen and antigenantibody complexes also activate blood coagulation through factor XII; some of the materials released from these platelets affect the vessel wall. The initial platelet mass is transformed to a fibrin mass. There are compounds that inhibit the platelet release reaction, platelet aggregation, and blood coagulation and activate the fibrinolytic mechanism. It appears that by the selective use of these compounds we can improve our management of all aspects of thromboembolic disease related to vascular and intravascular stimuli. Additional Indexing Words: Platelets Infarction C ONSIDERABLE concern has been expressed by governments and community groups about the failure of medicine to apply the knowledge gained from fundamental Blood coagulation research to the management of human disease in the control of a number of conditions, such problems. In the field of cardiovascular diseases significant advances have been made as high blood pressure, but in one area we have not yet made much impression. This is in thromboembolic disorders that affect not only the heart but other organs as well. If we could make a significant advance in the management of thromboembolic disease, we would produce a great improvement in adult human health. The majority of middle-aged persons in the western world die from a cardiovascular disorder. A prominent factor in the morbidity and death from cardiovascular disorders is thromboembolism, and myocardial infarction is one of the important manifestations of it' (table 1). Myocardial infarction, many strokes, some renal disease, and much peripheral vascular disease are almost invariably associated with diseased arteries. A high proportion of these diseased arteries is affected by mural and occlusive thrombi that play a significant part in causing dysfunction of the affected organ. 24 Numerous attempts have been made to institute measures for the management of thromboembolic disorders. Twenty years ago we thought we had a form of treatment for thrombosis and its complications; this was anticoagulant therapy designed to prevent or reduce fibrin formation. This therapy proved effective for the management of venous thromboembolism, particularly during the postoperative period and in complications associated with pregnancy.5' 6 Anticoagulant drugs, however, have not produced any significant effect on the overall morbidity and mortality from the complications of arterial disease such as myocardial infarction and strokes. [7] [8] [9] Assuming that thrombosis is in- volved in the death of patients with vascular disease who die from strokes or myocardial infarcts, this evidence indicates that drugs such as dicumarol are relatively ineffective in the management of arterial thrombosis. These clinical findings are not incompatible with what we know about the formation of thrombi; venous thrombi have a large coagulation component and therefore should be susceptible to the action of the orally administered anticoagulants. In contrast, thrombi that form on the arterial side have a smaller coagulation component and, therefore, may be less susceptible to the action of such anticoagulants. These drugs are also relatively ineffective in the management of femoral-popliteal bypass grafts and the complications of cardiac prosthetic valves.0' 11 The enthusiasm with which anticoagulant therapy was adopted for the treatment of arterial thrombosis indicates that the differences between arterial and venous thrombi were not taken into consideration. This is curious because investigators such as Bizzozero, 12 Eberth and Schimmelbusch,13 and Welch14 in the 1880's clearly demonstrated that arterial thrombi were initially composed of aggregated platelets and were not blood clots. Hence the rationale behind the use of anticoagulant drugs to prevent the initial accumulation of the platelet mass, which is the primary event in the formation of arterial thrombi, is open to serious question.
The knowledge acquired during the past 10 years reinforces the initial observations of the investigators in the 1880's and indicates that we do have new approaches to the diagnosis and management of thromboembolic disease, particularly arterial thromboembolism. These observations also indicate that the dimensions of thromboembolic disease are much greater than have been appreciated. This review will consider some of the recent evidence related to blood platelets. It will not be possible to discuss other components of the problem which are important and deserve consideration, such as the fibrinolytic mechanism and blood coagulation.
Thrombosis
An arterial thrombus formed from flowing blood is initially composed of aggregated platelets with some fibrin around the platelet aggregates. 15 Thrombosis and hemostasis represent the same reaction-the response of the blood to vessel wall injury. As far as we can tell, the mechanisms involved in each of these processes are the same. 16 When a blood vessel is cut, a mass of aggregated platelets plugs the cut vessel within 3 to 4 min. This is the process of hemostasis. The platelet mass extends from the tissue at the margins of the cut vessel across the lumen, and fibrin forms around the periphery of the aggregated platelets. The fact that the same mechanisms are involved in hemostasis and thrombosis poses a therapeutic dilemma. Can we inhibit thrombosis without altering hemostasis? The evidence indicates that we can.
Blood responds not only to vessel wall injury but also to intravascular stimuli.17 A mass of loosely aggregated platelets in a kidney capillary is shown in figure 1. This mass of aggregated platelets is not related to vessel wall injury and has been formed by an intravascular stimulus. In this particular case the stimulus was an antigen-antibody complex. We may look upon the reaction in which platelets can be made to aggregate as a general response of the blood to injury. The injury or stimulus can involve exposure of the subendothelial tissues in the vessel wall or the occurrence in the circulation of materials that can aggregate platelets. Intravascular stimuli include antigen-antibody complexes, viruses, bacteria, endotoxin, adrenaline, serotonin, thrombin and trypsin.'8
Platelet Aggregation
To understand the response of blood to injury, it is essential to understand the mechanism involved in the formation of the platelet aggregates. This can be divided into three parts: (1) release of platelet constituents stimulated by connective tissue in the vessel wall or constituents in the blood such as antigen-antibody complexes, (2) the adher-Circulation, Volume XLII, ence of platelets to each other induced by adenosine diphosphate (ADP) which can be released from the platelets by the stimuli just listed or from other injured cells; and (3) the influence of blood coagulation on platelet aggregation and on the stabilization of these aggregates by formation of fibrin.19
The Adherence of Platelets to Each Other When platelets are exposed to ADP, they change from their characteristic disc shape to a more rounded form with pseudopods ( fig.   2 ). In the presence of calcium and motion the altered platelets are then able to adhere to each other. This process can be studied in vitro by placing platelets in a suspending fluid and stirring them while a light beam passes through the suspending fluid. As the platelets aggregate, light transmission increases and can be recorded. After the platelets are aggregated by ADP, they quickly deaggregate ( fig. 3 ), and they eventually return to their original disc shape and again become responsive to ADP. Although there has been some indication from in vitro studies that ADP can cause release of platelet ADP and thereby further platelet aggregation, there is no evidence that ADP can cause irreversible aggregation either in vivo or in vitro.'8 It is possible that the apparently irreversible platelet aggregates induced by ADP in vitro are an artifact of the in vitro test system. The mechanisms involved in ADP-induced platelet aggregation have not been established. However, it is known that divalent cations are required20; calcium is essential for aggregation, and magnesium appears to be important in deaggregation.20 21 Metabolic energy is involved, and if the platelets lack glucose or are unable to utilize it, they become unresponsive to ADP.22'23 In addition, the platelets contain a contractile protein that resembles actomyosin,24 and it is believed that this is important in the process of platelet aggregation and deaggregation.25 Recently there has been considerable interest in a possible role for cyclic AMP in the process of platelet aggregation and deaggregation.2628 This electron micrograph shows loosely aggregated platelets in a rabbit glomerular capillary. Platelet aggregation was caused by the intravenous injection of an antigen-antibody complex. The platelets (PLT) have formed pseudopods (PSD) and are loosely adherent to each other. The endothelium (END) lining the capillary is not altered. The basement membrane (BM) is evident. X 21,600.
The Platelet Release Reaction
When platelets are exposed to collagen or other stimuli such as antigen-antibody complexes, they adhere to it ( fig. 4 ). In contrast to COrculaiton, Volume XLI!, July 1970 have osmiophilic storage granules that contain serotonin, histamine,31 32 and adenine nucleotides (ATP and ADP) that are not part of the metabolic pool.33 When the platelets interact with collagen, the amines and nucleotides are discharged from these granules; the reaction is called the "release reaction of platelets." This mechanism appears to be similar to the stimulus-secretion coupling mechanism described for other granule discharge processes such as that of the adrenal medulla.34 3 The release reaction in platelets involves metabolic energy and divalent cations,22' 36 and it is differentiated from the nonspecific release of cell constituents that occurs when platelets are lysed. The platelets also contain granules that have the properties of lysosomes in that they contain enzymes such as beta-glucuronidase, acid phosphatase, and cathepsin.37-39 Some of these enzymes are released into the surrounding fluid when platelets are stimulated with collagen.40 Also released is another factor or factors that cause contraction of smooth muscle and increased vessel permeability. 17' 41 One of the permeability factors released from the platelets may be similar to the cationic protein released from leukocyte granules.42 Recently, it has been reported that platelets also contain elastase that can be released.43
Antigen-antibody complexes can also cause the release of platelet constituents.44 Viruses and bacteria can cause platelet clumping, but it has not been established that they cause the same degree of release of platelet constituents although in vitro it can be shown that they do cause release of platelet nucleotides and serotonin.17 Endotoxin causes platelet aggregation,45 but it is believed that this involves the process of immune adherence'8 46 as well as the release reaction. 18 Another dimension to the reaction of platelets with intravascular stimuli is that the platelets can phagocytose particulate matter such as antigen-antibody complexes and viruses.47 Platelet phagocytosis of particulate matter resembles leukocyte phagocytosis of particulate matter in many ways.
Blood Coagulation and Platelet Aggregation
The relationship between platelet aggregation and blood coagulation is complex. When platelets are aggregated by ADP, the platelet phospholipoprotein at the membrane is exposed and accelerates the clotting reaction.48-51 This phospholipoprotein is involved in interactions between factors IX and VIII and between factors X and V.52, 53 In addition, a number of clotting factors are absorbed on the platelet membrane.54 Thrombin is generated in the area of the platelet aggregates at a rate faster than it can be diluted by flowing blood and neutralized by antithrombin. The thrombin can cause the release of further platelet constituents in the same manner as collagen and antigen-antibody complexes.18'33 Thrombin also causes the conversion of fibrinogen to fibrin, further accelerates the coagulation process,55, 56 and activates the fibrin stabilizing factor, factor XIII.57 These observations may explain why coagulation initially occurs around the surface of the platelet aggregates and why, in electron micrographs of freshly formed thrombi or platelet aggregates, the fibrin is interspersed only among the platelets at the surface.'5' 58, 59
Figure 4
This electron nzicrograph shows the efect of antigen-antibody complexes (ferritin-antiferritin) added to a suspension of washed pig platelets (PLT). The ferritin-antiferritin (FE-AFE) is in contact with the platelet membranes and these platelets have released their contents under the influence of this stimulus. Some of the platelets appear to have breaks in their membranes (arrows). X 22,500.
Other Factors Influencing Platelet Aggregation Epinephrine (adrenaline) and norepineph-Circulation, Volume XLII, July 1970 rine (noradrenaline) can cause platelet aggregation.60, 61 The mechanism by which adrena-
Figure 5
The electron micrograph shows a platelet mass in contact with collagen (COL) in the connective tissue of an injured mesenteric vessel. The platelets (PLT) in contact with the collagen are less electron dense than those at the top of the picture. The platelets in this region have retained their organelles and are tightly adherent to each other. Some fibrin (FIB) is interspersed among the platelets that have interacted with the collagen. X 9,000. Circulation, Volume XLII, July 1970 line induces platelet aggregation appears to be related in part, at least, to the release of platelet ADP.40 62 In addition, adrenaline potentiates the action of ADP and thrombin in causing platelets to aggregate. Adrenaline also accelerates blood coagulation.66 Serotonin is another platelet constituent that can be released and causes platelet aggrega-tion60' 67; its effect, however, is transient compared to that of adrenaline.
The Structure of a Thrombus
The structure of a thrombus newly formed from flowing blood reflects the mechanisms that have been discussed.'5 Where the platelets are in contact with the connective tissue in the vessel wall, they are adherent to it but have lost their constituents ( fig. 5 ). Other platelets are adherent to the platelets that are in contact with the collagen. Platelets farther removed from the vessel wall are more intact although their shape is altered ( fig. 5 ). These platelets are adherent to each other, have formed pseudopods but have retained most of their organelles. There is some variation in electron density of the platelets, probably because of the platelet swelling that is known to occur upon exposure to ADP. (ADP is responsible for the adherence of the platelets to each other.) Around the periphery of the aggregate the platelets are altered and many appear to have lost their internal structure. Some of the apparently empty platelets may be swollen pseudopods from the platelets toward the center of the aggregate. The degranulated platelets at the periphery probably represent those that have been affected by the thrombin. Surrounding these platelets and interspersed among them is fibrin ( fig. 5 ). In this region, red blood cells are often trapped. During the first few hours after the thrombus forms, polymorphonuclear leukocytes accumulate.
Inhibition of Platelet Aggregation
A variety of compounds have been described which inhibit ADP-induced platelet aggregation. These compounds include adenine compounds, prostaglandin El, methylxanthines, pyrimido-pyrimidine compounds, Circulation, Volume XLII, and a number of other compounds, many of which are used as vasodilators, such as nitroglycerin and intensain. '8 In in vitro studies, prostaglandin El has been found to be the most potent of the inhibitors of aggregation;68' 69 2-chloroadenosine70 has also been found to be extremely active, as has a derivative of AMP, 2-methylthio-AMP.71 Since almost all of these compounds also have vasodilator effects, they have not proven too useful for in vivo inhibition of platelet aggregation. 72 Nevertheless, their action on platelets raises some interesting considerations in respect to the mechanism of ADP-induced platelet aggregation. Prostaglandin El activates the adenyl cyclase of platelets and enhances the cyclic AMP level.26 Methylxanthines inhibit phosphodiesterase,73 an enzyme that normally breaks down cyclic AMP. These effects have led some investigators to believe that cyclic AMP is involved in the process of platelet aggregation, and the evidence indicates that a diminution in platelet cyclic AMP is associated with platelet aggregation.28
Inhibition of the Platelet Release Reaction
Many of the compounds that inhibit ADPinduced platelet aggregation will, in higher concentrations, also inhibit the release of platelet constituents induced by stimuli, such as collagen, or antigen-antibody complexes.'8 The adenine compounds (ATP, AMP, and adenosine), prostaglandin El, methylxanthines, and the pyrimido-pyrimidine compounds are also inhibitors of the platelet release reaction. In addition to these compounds, the nonsteroidal anti-inflammatory drugs74 75 and the imipramine type of com-pounds40 inhibit the release reaction. These compounds differ from the others in that they do not inhibit ADP-induced platelet aggregation. Lipids influence this process, and it has been demonstrated that phosphatidylserines inhibit the platelet release reaction. 76 When platelets are exposed to nonsteroidal anti-inflammatory drugs such as sulfinpyrazone, acetylsalicylic acid (aspirin), or the imipramine type of compounds before the addition of collagen, collagen-induced aggregation is inhibited, and this is associated with diminished release of platelet constituents such as the adenine nucleotides and serotonin. It is believed that this inhibition of the release of platelet constituents prevents collageninduced platelet aggregation. Not only is this true for collagen, but also for antigenantibody complexes and low concentrations of thrombin.74, 75, 77
The in Vivo Effect of Inhibition of
Platelet Aggregation
As mentioned earlier in this text, the formation of a hemostatic plug at the end of a cut vessel is a similar process to that involved in thrombosis. It is possible, therefore, to use the process of hemostasis to examine whether changing platelet function by the administration of compounds that inhibit platelet aggregation, the platelet release reaction, or a combination of both influences the response of the blood to vessel injury. It can be seen from table 2 that the administration to rabbits of drugs in doses that inhibit the reaction of platelets with collagen or inhibit ADP-induced platelet aggregation leads to a significant prolongation of the total bleeding time. Each value in this table represents the mean of 10 or more experiments. The total bleeding time reflects the time during which bleeding from the cut vessel occurred during 30 min of direct observation. These findings probably explain several well-known clinical observations. Aspirin has been known for years to be associated with gastrointestinal bleeding. 80 Although it has effects on the mucosa of the gastrointestinal tract, it is apparent that its inhibition of platelet function could be a contributing factor to the bleeding seen with this compound.
Another complication of the use of nonsteroidal anti-inflammatory drugs is their effect on the development of spontaneous hemorrhagic episodes in subjects receiving oral anticoagulant therapy.8' It was observed in rabbits that dicumarol or phenylbutazone, in doses that alone did not alter the primary and total bleeding time, did cause marked impairment of hemostasis when given together in such doses. 19 In these circumstances, two of the three primary mechanisms in hemostasis were altered; that is, the reaction of platelets with collagen or basement membrane, or both, and the ability of the blood to generate thrombin for the blood coagulation reaction. Thus, partial inhibition of two of the three mechanisms involved in the response of blood to injury leads to a severe impairment of hemostasis.
Circulation, Volume XLII, July 1970 Heparin is of interest in this respect because it is not only an anticoagulant but, when given in higher doses, it can inhibit the platelet response to collagen and to ADP.82 When heparin is given in doses that are conventionally used for an anticoagulant effect, it has only a slight effect on hemostasis. However, when it is given in higher doses that influence platelet function as well, it severely impairs hemostasis. 19 Another method by which these inhibitory compounds can be studied is in extracorporeal shunts. These shunts, which have been described in detail elsewhere,83 provide a surface with which blood interacts as it does with prosthetic materials. In these experiments the shunt contains a bifurcation and is connected to the carotid artery and jugular vein of the experimental animal. The amount of deposit formed in the bifurcation of the shunt after blood has flowed through it can be weighed. In table 3 the results from a number of experiments are shown. The difference in the mean amount of deposit in the control groups is due to the different times of blood flow used in the separate experiments. Aspirin and phenylbutazone75, 83 decrease the amount of deposit formed in the bifurcation of the shunts when compared with the corresponding control. Dipyridamole has been shown to inhibit thrombus formation in other experimental situations.85
Circulation, Volume XLII, Three of the compounds that inhibit the platelet release reaction or platelet aggregation are known to be active in man. Dipyridamole reduces the incidence of thromboembolism in patients with prosthetic heart valves86 and inhibits platelet aggregation.87 Aspirin prolongs the bleeding time in man88 and prolongs platelet survival. 84 Aspirin has a property that the nonsteroidal anti-inflammatory drugs do not appear to have; that is, the effect of a single dose of aspirin may last for several days.89 This may or may not be a beneficial effect, depending upon the circumstances. Sulfinpyrazone is one of the more interesting compounds since it was with this material that the initial observation of the effect of these drugs on platelets in man was made.90 Sulfinpyrazone is a uricosuric agent with relatively little anti-inflammatory action. 91 Nevertheless, it is highly effective in inhibiting the platelet response to stimuli such as collagen, and it has been used for long-term therapy of gout in man with minimal toxic effect.
The effectiveness of these compounds in man is perhaps best demonstrated by their action on the rejection episodes that occur in transplanted human kidneys. Between the seventh and 50th day after transplantation of kidneys, rejection episodes can occur that are associated with anuria and accumulation of large masses of platelets in the renal ves-sels.Y2 9 This work has been developed largely by Mowbray93 and Porter's group92 and confirmed in other experiments, particularly in experimental animals. 94 Biopsies of kidneys taken from individuals during these rejection episodes show platelet aggregates plugging the lumen of the vessels of the transplanted kidney. Study of the behavior of 51Cr-labeled platelets in these individuals has demonstrated accumulation of the radioactivity over the transplanted kidney during a rejection episode. If, at this time, compounds that inhibit platelet aggregation are administered, the radioactive platelets leave the kidney and return to the circulation. Renal function is restored. The platelets that return to the circulation appear to have the same survival time as that of platelets from patients not undergoing a rejection episode. In the studies of Mowbray93 and Porter,92 azothioprine (Imuran) and prednisone have been used as well as phenylbutazone. Imuran and prednisone inhibit the platelet response to surface stimuli such as collagen.93 These studies also indicate that in the early stages, thrombi are in a balance between formation and dissolution. If the balance is tilted in favor of dissolution, the mass disappears. Earlier studies by direct observation of thrombi in the microcirculation indicated that this was the case.95
Response of the Blood to Injury and Disturbances of the Microcirculation
The concept of thrombosis is mainly centered around the process in large vessels. However, the mechanisms involved in the response of the blood to injury'8 indicate that intravascular platelet aggregates may be formed and have a significant effect on the microcirculation. This process may be important in defining the mechanisms involved in tissue injury including some forms of myocardial infarction.
A problem in studies of coronary artery disease has been that it has not been possible to show good correlation between occlusion by thrombosis of main coronary arteries and myocardial infarction. The incidence of coronary thrombosis in patients dying of myocar-dial infarctions in various studies has ranged from 30 to 90%, with an average of about 60%.2, 96-99 A number of suggestions have been made to explain the failure to find occlusive thrombi in association with all forms of myocardial infarction. These include rupture of atherosclerotic plaques with immediate death, hemorrhage into a plaque, obstruction of the microcirculation, abnormal blood flow, or abnormal metabolism. 100 One possibility is that showers of platelet emboli in the coronary circulation lead to myocardial injury. There is evidence from studies of the cerebral circulation that showers of platelet emboli arising from the thrombi at the bifurcation of diseased carotid arteries can produce dysfunction of the cerebrum.101' 102 To explore this theory in respect to the myocardium, transient platelet aggregates were introduced into the myocardial circulation of swine by the infusion of ADP.103 When such an infusion is given, the platelet count falls but fairly quickly returns to normal when the infusion is stopped. In these experiments, the ADP was infused for a period of 5 min. In association with a fall in platelet count induced by the formation of platelet aggregates, the microcirculation was arrested, arterial blood flow was intermittently obstructed, and venous blood flow ceased. Histologic examination of myocardial tissues taken at the time of the infusion showed that the vessels in the myocardium were plugged with platelet aggregates. Two to 3 hours after such an infusion, more than 80% of the pigs given ADP developed myocardial infarcts. In contrast, none of the thrombocytopenic animals, nor the animals with platelets refractory to ADP, developed infarcts after ADP infusion. Only 17% of the pigs infused with AMP (a compound that does not cause platelet aggregation) developed small infarcts. In the experiments with ADP infusions, platelet aggregates were found in the sections taken from all the animals during infusion. However, platelet aggregates were found in only 33% of the animals killed 5 min or longer after the infusion. Thus, it is not possible to establish by histologic means that platelet aggregates in the myocardial circulation have caused the myocardial infarct. Recently, Robbins and associates104 have confirmed these experiments in pigs. Also, myocardial infarction in a dog has been described which was associated with platelet aggregates and a lack of extensive disease in the coronary arteries. 105 The relationship of this process to human disease is not clear. In a study of human postmortem tissue, few platelet aggregates were found in the myocardial vessels of tissues taken at consecutive autopsies.100 In the patients dying with myocardial ischemia, the incidence of platelet aggregates was about the same as that found in the swine given ADP and killed after the infusion of ADP.103 In the group of patients with no coronary obstructions, 31% had platelet aggregates in the arterial vessels. Thus platelet aggregates in the microcirculation may be one of the causes of death of individuals with myocardial ischemia who do not have a main coronary artery obstructed.
Another organ in which platelet aggregates or emboli have been shown to be important in the production of tissue injury -and subsequent changes is the kidney. Moore and Merse-reau3 106, 107 have shown in human and animal investigations that embolization of material from mural thrombi in the aorta into the renal circulation can produce focal renal lesions that can be associated with permanent elevation of the blood pressure. In experiments with rabbits, the transient platelet thromboemboli induced by ADP were found to cause acute focal glomerular nephritis.108 109 This acute change in the kidney was followed by chronic changes leading to some degree of glomerular scarring. Acute effects were associated with hematuria and proteinuria, and numerous casts were also found in the kidneys of the ADP-infused animals. These rabbits developed permanent elevation of the systolic blood pressure. Rabbits with platelets refractory to ADP did not develop this change, nor did those animals infused with AMP.
This evidence indicates that transient platelet aggregates in the microcirculation of an Circulation, Volume XLII, July 1970 organ could be involved in dysfunction and the development of tissue injury. In the swine experiments, it was not at all unusual to find animals developing an arrhythmia (such as ventricular fibrillation) and dying d-uring the actual infusion. 103 Although it will be difficult to prove that this is a mechanism in the development of human disorders, the animal experiments indicate that it must be taken into consideration and that we may find that in the management of thromboembolic disease our therapeutic measures may have an effect far greater than we would ordinarily anticipate on the basis of the more conventional evidence. The intravascular stimuli that can induce platelet aggregates in the microcirculation include (as discussed previously) thrombin, antigen-antibody complexes, viruses, and bacteria.'7 The effect of these stimuli can also be studied in respect to the changes in the pulmonary circulation.
The intravenous infusion of antigen-antibody complexes into rabbits causes the formation of platelet aggregates in the pulmonary vessels.41 This is associated with a fall in the arterial pressure and a rise in the venous pressure. This change has usually been attributed to antigen-antibody complex aggregates blocking the pulmonary circulation."10 However, if the animals are treated with nonsteroidal anti-inflammatory drugs, such as aspirin and sulfinpyrazone, the fall in the platelet count caused by the infusion of the antigenantibody complex can be prevented.4' When rabbits are treated in this manner, there is no fall in the arterial pressure or rise in venous pressure associated with the infusion of the antigen-antibody complexes. Furthermore, histologic examination of the lungs fails to reveal platelet aggregates in the pulmonary bed. Thus, if platelet aggregation by antigenantibody complexes is inhibited, the fall in arterial pressure and rise in venous pressure are prevented. It appears therefore that the blood pressure changes seen in the anaphylactic response to the intravenous infusion of antigen-antibody complexes are at least initially related to platelet aggregation and not just to trapping of antigen-antibody complexes in the pulmonary circulation.
The intravenous infusion of endotoxin is known to be associated with collapse of arterial pressure and rise of venous pressure with the development of shock in rabbits.",' If rabbits are treated with drugs such as sulfinpyrazoine, phenylbutazone, acetylsalicylic acid, or sodium salicylate before the intravenous infu-sion of the endotoxin, the platelet count does not fall and the blood pressure is maintained.i 112 Histologic examination of the treated animals shows that the endotoxin does not cause platelet aggregation in the pulmonary bed such as is seen in the untreated animals. It is of some interest in these studies that the fall in the white count, which also occurs with endotoxin infusion, does not occur when the animals are treated with the nonsteroidal anti-inflammatory drugs. There is evidence that endotoxin initially reacts with the platelets in the circulation.45 118 It is clear that prevention of this endotoxin interaction with platelets protects the animals from the acute effects of the endotoxin infuision,
One of the consequences of repeated stimulation of the blood with endotoxin is the formation of fibrin deposits in the kidney, giving rise to the generalized Shwartzman reaction.114 It appears that one mechanism of formation of this fibrin deposit is througlh the action of endotoxin on platelets. It is recognized that endotoxin can also accelerate blood F a'. ..i. E Figure 6 An arctnate vein of a rabbit kidneyl ho liours after the intra-aortic infusion of ADP. Thrombi (TH) can be seen1 in the ltumen of the vein anid twhere the thrombi are in conltact with thze vessel wall, 11unuerouis poljmorphonuclear leukocytes have accuimulated (arrows). In the ripper r'ight portion of the picture, the periadventitial space is filled with an amorphous material and thisnmta represent edemaIa. Lendut ni's inartius-scarlet-blue. 120 X 300.
Circuantion, Volume XLII, Jol) 1970 coagulation"14 and that blood coagulation could initiate the formation of fibrin deposits in the kidney. If rabbits infused with endotoxin are treated with nonsteroidal anti-inflammatory drugs, the renal lesions characteristic of the generalized Schwartzman reaction can be prevented.41 112 These observations indicate that the acute vascular syndromes associated with bacterial infection may be altered by the use of compounds that inhibit platelet aggregation. These studies also indicate that the response of blood to injury is a wider subject than just the effects of occlusive thrombi in large veins and arteries.
Platelet Aggregation and Vascular Injury
It is not uncommon to find vasculitis in association with some of the reactions that have been discussed in the previous section. Leukocytes can initiate alterations in the vessel wall and increase vessel permeability."5' 116 They are considered to be important in causing the vascular changes seen with many intravascular-immunologic reactions such as the Arthus and localized Shwartzman reactions. Hughes and Tonks"17 118 have suggested that platelet aggregates may also initiate vasculitis. In the experiments described previously with ADP, 103, 108, 109, 119 a vascular reaction frequently could be detected in association with the platelet aggregates ( fig.  6 ). In these studies it was not uncommon to find the endothelium lost from the side of the thrombus close to the vessel wall and occasionally the internal elastic lamina was also disrupted. This is of some interest, since it has now been shown that the platelets can release an elastase43 which could result in the loss of elastin from the area in which the platelet mass is in contact with the vessel wall. In many of these vascular reactions intense polymorphonuclear leukocyte accumulation was found in the vessel wall at the site of contact with the platelet aggregate. In the experiments in pigs and rabbits, about 28% of the animals infused with ADP had this type of vascular lesion, whereas only 3% of the animals with refractory platelets infused with ADP had such lesions.109 None of the animals Circulation, Volume XLII, July 1970 infused with AMP developed vasculitis. It seems likely that these vascular lesions may have been caused by the release from the platelets of factors that cause increased vessel permeability, chemotaxis of leukocytes, '7 121 and possibly dissolution of structures in the vessel wall.
The relevance of the formed elements and vessel injury to the development of atherosclerosis also must be taken into consideration. There is no doubt that organized mural thrombi can contribute to the thickening of the vessel wall and therefore to the development of the atherosclerotic lesion.'22' 123 Obviously this is not the only mechanism, and it is very difficult to implicate it in the development of "the early stages." However, examination of the sites of predilection for the early changes in the vessel wall indicates that these sites are areas where there is increased permeability of the endothelium with edema of the intima and an accumulation of leukocytes and platelets on the endothelial surface.124 Since these are regions where disturbed blood flow frequently occurs and since disturbed blood flow localizes the site of accumulation of the formed elements on the vessel wall, it is possible that the formed element interaction with the vessel wall at these sites is the reason for these localized areas of vessel injury and increased vessel permeability. 124 126 Clearly, areas of vessel injury with increased endothelial permeability would facilitate the accumulation of plasma proteins (in particular plasma lipoproteins) in the intima. 127 Since beta-lipoproteins are known to be poorly cleared from tissues'28 and to initiate cellular proliferation, the interactions of blood flow, the formed elements, the plasma proteins, the lipoproteins, and the increased vessel permeability could well be an explanation for the characteristic localization of the early changes in atherosclerosis. No one theory of atherosclerosis can be considered to the exclusion of the others.
Environmental Factors and Thromboembolism
There is epidemiologic evidence that high fat diets are associated with an increased susceptibility to arterial and venous thrombo-SiS. 129 Connor and his associates130' 131 have shown that long-chain saturated fatty acids can enhance blood coagulation and cause platelet aggregation. It has been proposed that the effect of fatty acids on platelets occurs when the molar ratio of fatty acids to albumin exceeds 2. They found that stearic acid and oleic acid caused the formation of persistent pulmonary platelet aggregates. Haslam62 showed that fatty acids caused the release of platelet nucleotides if the fatty acids were not bound to albumin. Fatty acids may not have as extensive an effect in vivo where presumably there is enough albumin to bind most of the unesterified fatty acids. However, as Connor and associates'3l have pointed out, if the sites on albumin are saturated, the excess fatty acids might then affect the platelets.
Recently Renaud and associates132 have observed that when rats were maintained on a diet rich in butterfat, they were more susceptible to endotoxin-induced thrombosis and their platelets were more responsive to thrombin than control rats maintained on a low fat diet. In these experiments, rats maintained on a diet rich in corn oil showed less change than the animals given the diet rich in butterfat. The enhancement in platelet response to thrombin produced by the butterfat diet remained when the platelets had been washed free of plasma proteins. These studies show that dietary fat can induce changes in the platelets which alter their sensitivity to the stimuli that cause platelet aggregation. Other studies have indicated that when animals are given certain types of diet, the persistence of ADP-induced platelet aggregates is enhanced.'33 Pigs maintained on a diet rich in egg yolk for a year, formed more deposit in an extracorporeal shunt than animals given a low fat diet.'26 Animals given a diet rich in lard formed less deposit in the shunt than those given egg yolk. In these studies there was no detailed examination of whether the diets produced significant changes in platelet function.
Diet also influences platelet function in man.
In a study of seven patients maintained in a metabolic ward, platelet survival was shortest and platelet turnover greatest when the patients were fed a diet rich in butterfat and egg yolk.134 Platelet survival was longest and platelet turnover smallest when the patients were given a low fat diet. Since, as discussed earlier, platelet survival reflects platelet function, these studies show that dietary fat influences platelet function in man.
Smoking is known to be associated with the development of vascular disease and its complications,'35 and nicotine can cause platelet aggregation.'30 When subjects were maintained in a metabolic ward and given a constant diet, platelet survival was shorter, and platelet turnover was greater during the period in which they were allowed to smoke than during the period in which smoking was restricted.137 The stress of being prohibited from smoking may have affected the study, but it does seem likely that cigarette smoking influenced platelet function in these subjects. There is conflicting evidence as to whether smoking affects platelet adhesiveness. 138 Many attempts have been made to develop technics for measuring what is commonly referred to as "platelet stickiness" or platelet adhesiveness. The assumption has been that the development of such a technic might be useful in the management and diagnosis of thromboembolic disease. A number of studies indicate that subjects who have recurrent episodes of thromboembolic disease have increased "platelet stickiness." One might better describe these tests, however, as indicative of increased platelet retention when blood is passed through or over glass bead surfaces.'8' 139 One set of results shows that tests of platelet adherence to surfaces or platelet retention in glass bead columns reflect susceptibility to intravascular thrombosis.10 Subjects who were going to receive femoral-popliteal bypass grafts had their blood passed through a glass bead column. Samples from some patients showed high platelet retention, and from others, low platelet retention. The subsequent follow-up of these patients after the surgical procedures showed that those individuals who had a high platelet retention in the glass bead column had the earliest occlusion of their Dacron or vein grafts. Individuals with low platelet retention showed the lowest incidence of graft occlusion.'0 The Fate of Thrombi In our understanding of the response of blood to injury the resolution and organization of thrombi are also important. It was recognized early that an initial platelet-rich mass would rapidly transform to a mass of fibrin.14 More detailed studies recently have shown that at 1 hour the thrombus is composed of aggregated platelets surrounded by fibrin."5 By 24 hours the platelets have been replaced by fibrin. In this process the platelets separate from each other, plasma seeps between the platelets, and clotting occurs. The platelets disintegrate so that the picture at 24 hours, as seen in the electron microscope, is of a mass of fibrin with platelet debris interspersed among the fibrin fibers. The thrombus material is rapidly invaded by polymorphonuclear leukocytes, and by 24 hours, mononuclear cells are present. By 11 days a thrombus of this type is organized into a lesion full of young smooth muscle cells and connective tissue and covered with endothelium. It is important to emphasize that a transformed platelet-rich thrombus at 24 hours does not have the appearance of a blood clot. The age of an arterial thrombus obviously will influence the type of therapy that should be used to cause its dissolution. 
